Inflammatix Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 73

Employees

  • Latest Deal Type
  • Series E

  • Latest Deal Amount
  • $57M

  • Investors
  • 20

Inflammatix General Information

Description

Developer of molecular diagnostic tests designed to interpret the immune system to diagnose acute infections and assess illness severity. The company's tests measure specific messenger RNA markers in blood samples to provide bacterial and viral infection likelihood and severity scores, enabling emergency departments to make timely clinical decisions and improve patient management with data-driven insights.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 540 Oakmead Parkway
  • Sunnyvale, CA 94085
  • United States
+1 (650)
Primary Industry
Diagnostic Equipment
Other Industries
Decision/Risk Analysis
Biotechnology
Corporate Office
  • 540 Oakmead Parkway
  • Sunnyvale, CA 94085
  • United States
+1 (650)

Inflammatix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Inflammatix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC (Series E) 12-Sep-2024 $57M Completed Product Development
12. Secondary Transaction - Private Completed Product Development
11. Grant 01-Jul-2023 Completed Product Development
10. Grant 11-Nov-2021 Completed Product Development
9. Later Stage VC (Series D) 14-Sep-2021 Completed Product Development
8. Accelerator/Incubator 22-Jun-2020 Completed Product Development
7. Later Stage VC (Series C) 10-Jan-2020 Completed Product Development
6. Grant 14-Nov-2019 Completed Product Development
5. Early Stage VC (Series B) 18-Oct-2018 $17.9M $22M Completed Product Development
4. Accelerator/Incubator 31-Mar-2017 $4.1M Completed Product Development
To view Inflammatix’s complete valuation and funding history, request access »

Inflammatix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D
Series C
Series B 8,250,918 $0.000010 8% $1.73 $1.73 1x $1.73 11.26%
Series A 6,192,310 $0.000010 8% $0.67 $0.67 1x $0.67 8.45%
To view Inflammatix’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Inflammatix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of molecular diagnostic tests designed to interpret the immune system to diagnose acute infections and assess
Diagnostic Equipment
Sunnyvale, CA
73 As of 2026

Seattle, WA
 

Birmingham, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Inflammatix Competitors (5)

One of Inflammatix’s 5 competitors is Immunexpress, a Venture Capital-Backed company based in Seattle, WA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Immunexpress Venture Capital-Backed Seattle, WA
ExGen Dx Venture Capital-Backed Birmingham, United Kingdom
CytoVale Venture Capital-Backed South San Francisco, CA
Sense Biodetection Formerly VC-backed Abingdon, United Kingdom
Autogenomics Formerly VC-backed Carlsbad, CA
You’re viewing 5 of 5 competitors. Get the full list »

Inflammatix Patents

Inflammatix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260249299-A1 Mastermix integration into cartridge-based in vitro diagnostics device Pending 21-Feb-2025
WO-2026178224-A1 Mastermix integration into cartridge-based in vitro diagnostics device Pending 21-Feb-2025
EP-4608557-A1 A fluidic device and methods for characterization of an infection or other condition Pending 24-Oct-2022
WO-2024091936-A1 A fluidic device and methods for characterization of an infection or other condition Inactive 24-Oct-2022
US-20240132963-A1 Fluidic device and methods for characterization of an infection or other condition Pending 24-Oct-2022 C12Q1/6883
To view Inflammatix’s complete patent history, request access »

Inflammatix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Inflammatix Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds
OSF Healthcare Corporation Minority
Raw Ventures Venture Capital Minority
Vesalius Biocapital Partners Venture Capital Minority
Defense Advanced Research Projects Agency Government
National Institutes of Health Government
You’re viewing 5 of 20 investors. Get the full list »

Inflammatix FAQs

  • When was Inflammatix founded?

    Inflammatix was founded in 2016.

  • Where is Inflammatix headquartered?

    Inflammatix is headquartered in Sunnyvale, CA.

  • What is the size of Inflammatix?

    Inflammatix has 73 total employees.

  • What industry is Inflammatix in?

    Inflammatix’s primary industry is Diagnostic Equipment.

  • Is Inflammatix a private or public company?

    Inflammatix is a Private company.

  • What is Inflammatix’s current revenue?

    The current revenue for Inflammatix is .

  • How much funding has Inflammatix raised over time?

    Inflammatix has raised $213M.

  • Who are Inflammatix’s investors?

    OSF Healthcare, Raw Ventures, Vesalius Biocapital Partners, Defense Advanced Research Projects Agency, and National Institutes of Health are 5 of 20 investors who have invested in Inflammatix.

  • Who are Inflammatix’s competitors?

    Immunexpress, ExGen Dx, CytoVale, Sense Biodetection, and Autogenomics are competitors of Inflammatix.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process